Room 99.1

Recursion provides up-to-date guidance on starting clinical trials

SALT LAKE CITY, March 3, 2022 — Recursion (NASDAQ: RXRX) today provided updated guidance on starting clinical trials:

Recursion’s management team decided that conducting a dose optimization study in a sheep efficacy model of Tay Sachs disease is prudent and in the best interest of patients before enrolling infants in a phase 2 trial of REC-3599 in the ultra-rare indication infantile GM2 gangliosidosis. This decision will delay the start of the GM2 phase 2 trial by approximately 2 years.

The Recursion Phase 2 Trial REC-994 in cerebral cavernous malformation is on track and we plan to enroll the first patient in the coming weeks.

Phase 2 of the Recursion Phase 2/3 Adaptive Trial of
REC-2282 in neurofibromatosis type 2 is on track to register in the second trimester.

The Recursion Phase 2 Trial REC-4881 in familial adenomatous polyposis is expected to enroll the first patient in the second or potentially third quarter of 2022 due to difficulties in opening the site presented by the Covid-19 Omicron variant.

Preparations for Recursion’s Phase 1 study on REC-3964 in relapsing C. difficile colitis are on track and we expect to begin recruitment in the second half of 2022.

About recursion

Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Its mission is the Recursion Operating System, a platform built on diverse technologies that continuously extends one of the world’s largest proprietary biological and chemical datasets, the Recursion Data Universe. Recursion leverages sophisticated machine learning algorithms to distill from its dataset the Recursion Map, a collection of hundreds of billions of searchable inferences about biology and chemistry unconstrained by human bias. Commanding a massive experimental scale – up to millions of wet lab experiments per week – and a massive computational scale – owning and operating one of the world’s most powerful supercomputers, Recursion unites technology, biology and chemistry to advance the future of medicine.

The company is proudly headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah Life Sciences Industry Collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more about www.Recursion.comor log on to Twitter and LinkedIn.

Media Contact

[email protected]

Contact Investor

[email protected]

Forward-looking statements

This document contains information that includes or is based on “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those relating to Recursion’s mission; discovery, pre-clinical and early-stage and late-stage clinical programs; licenses and collaborations; potential products and their potential future indications and market opportunities; Recursive operating system and other technologies; expansion of facilities and intended uses; workforce growth; employee stock exchange plans; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan”, “will”, “expect”, “anticipate”, “intend”, “believe”, “potential”, ” continue” and similar terms. These statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements, including, but not limited to: challenges inherent in research and pharmaceutical development, including the timing and results of preclinical studies and clinical programs, where the risk of failure is high and where failure may occur at any stage prior to regulatory approval due to insufficient efficacy, safety considerations or other factors; our ability to operate and improve our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaborative activities; our ability to obtain regulatory approval and ultimately commercialize drug candidates; the impact of COVID-19[female[feminine pandemic and force majeure events; our ability to obtain, maintain and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate and retain key employees and manage our growth; and other risks and uncertainties such as those described under “Risk Factors” in our filings with the United States Securities and Exchange Commission, including our most recent quarterly report on form 10-Q. All forward-looking statements are based on management’s current estimates, projections and assumptions, and Recursion undertakes no obligation to correct or update such statements, whether as a result of new information, future developments or otherwise. , except to the extent required by applicable law.